- Home
- GWH vs PASG Comparison
GWH vs PASG Comparison
Compare GWH & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWH
- PASG
- Stock Information
- Founded
- GWH 2011
- PASG 2017
- Country
- GWH United States
- PASG United States
- Employees
- GWH N/A
- PASG N/A
- Industry
- GWH Industrial Machinery/Components
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- GWH Miscellaneous
- PASG Health Care
- Exchange
- GWH Nasdaq
- PASG Nasdaq
- Market Cap
- GWH 27.6M
- PASG 27.6M
- IPO Year
- GWH N/A
- PASG 2020
- Fundamental
- Price
- GWH $6.47
- PASG N/A
- Analyst Decision
- GWH Hold
- PASG Strong Buy
- Analyst Count
- GWH 4
- PASG 4
- Target Price
- GWH $2.67
- PASG $59.25
- AVG Volume (30 Days)
- GWH 24.6M
- PASG 33.5K
- Earning Date
- GWH 11-12-2025
- PASG 11-12-2025
- Dividend Yield
- GWH N/A
- PASG N/A
- EPS Growth
- GWH N/A
- PASG N/A
- EPS
- GWH N/A
- PASG N/A
- Revenue
- GWH $6,166,000.00
- PASG N/A
- Revenue This Year
- GWH $131.04
- PASG N/A
- Revenue Next Year
- GWH $76.74
- PASG N/A
- P/E Ratio
- GWH N/A
- PASG N/A
- Revenue Growth
- GWH N/A
- PASG N/A
- 52 Week Low
- GWH $0.76
- PASG $5.12
- 52 Week High
- GWH $13.87
- PASG $26.60
- Technical
- Relative Strength Index (RSI)
- GWH 66.86
- PASG 64.44
- Support Level
- GWH $1.66
- PASG $8.00
- Resistance Level
- GWH $13.87
- PASG $8.97
- Average True Range (ATR)
- GWH 1.27
- PASG 0.49
- MACD
- GWH 0.63
- PASG 0.02
- Stochastic Oscillator
- GWH 37.62
- PASG 71.94
About GWH ESS Tech Inc.
ESS Tech Inc is a long-duration energy storage company specializing in iron flow battery technology. The company design and produce long-duration batteries predominantly using earth-abundant materials.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.